Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

(2019) Conan G. Kinsey et al.   NATURE MEDICINE

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

(2019) Kirsten L. Bryant et al.   NATURE MEDICINE

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

(2019) Margaret A. Tempero et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies

(2019) Kevin Lou et al.   Science Signaling

Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition

(2019) Meagan B. Ryan et al.   CLINICAL CANCER RESEARCH

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Fibroblast activation protein α-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation

(2019) Zhang Wen et al.   Annals of Translational Medicine

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

Gemcitabine and glioblastoma: challenges and current perspectives

(2018) Chiara Bastiancich et al.   DRUG DISCOVERY TODAY

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

(2018) Marta Román et al.   Molecular Cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes

(2018) Sebastian Mueller et al.   NATURE

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

(2018) Carmine Fedele et al.   Cancer Discovery

Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma

(2018) Kianna Y. Elahi-Gedwillo et al.   CANCER RESEARCH

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

Optimizing the outcomes of pancreatic cancer surgery

(2018) Oliver Strobel et al.   Nature Reviews Clinical Oncology

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

(2017) Vincent Chung et al.   JAMA Oncology

Pancreatic Cancer Chemoresistance to Gemcitabine

(2017) Manoj Amrutkar et al.   Cancers

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

(2017) Jonas Cicenas et al.   Cancers

Ras Conformational Ensembles, Allostery, and Signaling

(2016) Shaoyong Lu et al.   CHEMICAL REVIEWS

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients

(2016) Perrine Créquit et al.   LUNG CANCER

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer

(2016) J.-Y. Kim et al.   MOLECULAR CANCER RESEARCH

The role of wild type RAS isoforms in cancer

(2016) Bingying Zhou et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro

(2015) Volker Teichgräber et al.   Advances in Medical Sciences

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

(2015) Sarah J. Welsh et al.   Therapeutic Advances in Medical Oncology

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

(2013) Kamal S. Saini et al.   CANCER TREATMENT REVIEWS

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

The Pancreas Cancer Microenvironment

(2012) C. Feig et al.   CLINICAL CANCER RESEARCH

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

Analysis of Binding Site Hot Spots on the Surface of Ras GTPase

(2011) Greg Buhrman et al.   JOURNAL OF MOLECULAR BIOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Allosteric Sites on Ras for Lead Generation

(2011) Barry J. Grant et al.   PLoS One

Challenges of drug resistance in the management of pancreatic cancer

(2010) Rizwan Sheikh et al.   Expert Review of Anticancer Therapy

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER